Effects of Egg White Powder Supplementation on Nutritional Status, Biochemical Profile, and Oxidative Stress Markers in Diabetic Hemodialysis Patients; A Double‐Blind Randomized Controlled Trial Authors: Arvin Babaei, Hamta Abdollah Niya, Soudabeh Hamedi‐Shahraki, Javid Safa, Ali Tarighat‐Esfanjani Published: 2026 ABSTRACT ABSTRACTBackground and AimsProtein‐energy wasting (PEW) and oxidative stress (OS) frequently occur as complications in patients undergoing hemodialysis (HD), especially among those diagnosed with type 2 diabetes mellitus (T2DM). Egg white powder (EWP) is a low‐phosphorus, high‐ biological value protein source that may help improve nutritional and oxidative balance. This study aimed to evaluate the impacts of EWP supplementation on nutritional status, biochemical parameters, and OS markers in diabetic HD patients.MethodsIn this double‐blind, placebo‐controlled trial, 39 adult T2DM patients on HD were randomly assigned to receive either EWP (30 g; 22 g protein; 3 days/week) or a cocoa‐flavored placebo during HD sessions for 8 weeks. Primary outcomes included Nutritional indicators (BMI, dietary intake, serum albumin, phosphorus, and OS markers—total antioxidant capacity (TAC), superoxide dismutase (SOD), and malondialdehyde (MDA). ANCOVA adjusted for baseline values, body mass index, dietary intake, energy intake, and physical activity was used for group comparisons.ResultsProtein intake increased significantly in the EWP group, while phosphorus decreased. Serum albumin rose from 3.65 ± 0.62 to 4.15 ± 0.69 g/dL (p < 0.001). The lipid profile showed a significant improvement, with total cholesterol and LDL‐c levels reduced. Fasting blood sugar significantly declined. TAC, and SOD increased (p = 0.01 and p = 0.003), and MDA decreased markedly. Two deaths and one hospitalization occurred during the study; all were determined to be unrelated to the intervention. No intervention‐related adverse effects were reported.ConclusionEWP supplementation improved protein intake, albumin levels, lipid control, and antioxidant capacity in diabetic HD patients without increasing phosphorus burden. EWP may serve as a safe, functional nutritional supplement in renal nutrition therapy.Keywords: egg white powder, hemodialysis, oxidative stress, phosphorus control, protein‐energy wasting Abbreviations protein kinase B biological antioxidant potential body mass index cholecystokinin chronic kidney disease end‐stage renal disease egg white hydrolysate egg white powder fasting blood sugar glucose transporter type 4 hemodialysis high‐density lipoprotein cholesterol heme oxygenase‐1 insulin receptor substrate‐1 low‐density lipoprotein cholesterol mean difference malondialdehyde nuclear factor erythroid 2–related factor 2 probability value (statistical significance level) randomized controlled trial reactive oxygen species standard deviation superoxide dismutase statistical package for the social sciences total antioxidant capacity triglycerides Introduction Chronic kidney disease (CKD) is acknowledged as one of the most significant contributors to mortality in the 21st century, especially in the Middle East [1]. In 2017, approximately 843.6 million people were affected worldwide [2]. The global prevalence varies by region, age, sex, and socioeconomic status but is estimated at 13.4% (11.7–15.1) [3]. CKD is characterized by a persistent impairment in kidney structure and function for a duration exceeding 3 months [4]. This condition arises from the irreversible loss of nephrons and is classified according to the glomerular filtration rate and the presence of albuminuria, advancing from asymptomatic stages to end‐stage renal disease (ESRD) [4]. Among ESRD patients, those with diabetes experience significantly higher mortality rates, primarily due to cardiovascular comorbidities [5]. Between 2000 and 2015, the global prevalence of ESRD patients with diabetes increased from 19% to 29.7% [6]. Renal replacement therapies (RRT)—including kidney transplantation, peritoneal dialysis, and hemodialysis (HD)—are essential for sustaining life in ESRD patients [7]. Although kidney transplantation is the optimal treatment option for ESRD, challenges such as donor scarcity and immunosuppression limit its accessibility [8]. Consequently, the majority of ESRD cases (about 90%) depend on HD for survival [8, 9]. The prevalence of HD continues to increase, with an estimated 5.4 million patients expected by 2030 [10]. Nutritional management in HD poses exclusive challenges. While reduced animal protein intake is advantageous in early CKD, such restrictions are harmful during dialysis due to higher protein need [11]. Clinically stable HD patients require 1–1.2 g/kg/day of protein, at least 50% derived from high–biologic value sources [12]. Reducing protein intake below these recommended levels increases the risk of Protein‐energy malnutrition (PEW) [13]. Once dialysis is initiated, uremic symptoms such as nausea and vomiting improve over time, but reduced appetite, dietary limits, inflammation, and nutrient losses persist, contributing to PEW [14]. Poor nutritional status and electrolyte imbalances are associated with mortality in ESRD patients [15]. Consequently, dietary guidelines for ESRD emphasize adequate energy and protein intake along with strict monitoring of sodium, potassium, and phosphorus levels [16]. Increased oxidative stress (OS) is a well‐known factor associated with ESRD [17]. Mitochondrial damage increases OS through excess reactive oxygen species (ROS), in the nephron and leading to tubular injury [18]. OS begins early in CKD and increases as the disease progresses [19]. HD causes higher OS peritoneal dialysis, due to repeated blood contact with dialyzer membranes, which activates leukocytes and ROS formation [17]. Elevated malondialdehyde (MDA) is closely associated with cardiovascular disease risk, whereas antioxidant enzymes such as superoxide dismutase (SOD) decline in HD patients [20]. To prevent hyperkalemia, HD patients are often advised to limit potassium‐rich fruits and vegetables, which inadvertently reduces their intake of dietary antioxidants and vitamins [20]. Eggs are composed of three major components: shell (9%–12%), egg white (60%), and yolk (30%–33%) [21]. Egg white consists of water (87.8%) and protein (7.9%–10.6%), including ovalbumin, ovotransferrin, ovomucoid, ovoglobulin, and lysozyme, and a negligible amount of carbohydrates and fat [22]. It possesses diverse bioactivities, including antioxidant, antibacterial, immunomodulatory, ACE inhibitory, and hypoglycemic [23]. Ovalbumin hydrolyzed with enzymes such as alkali, trypsin, protamex, and α‐chymotrypsin showed protective effects against oxidation [24]. The goal of treatment in HD is to avert the advancement of potential complications and enhance the quality of life. HD patients often have limited food options due to the high phosphorus content of most animal proteins [25]. Egg white powder (EWP) is low in phosphorus, fat, and carbohydrates, and rich in high‐quality protein. Despite its potential benefits for phosphorus control and nutritional status [26]. The side effects include chronic pain, and the cost of HD medications and supplements makes them unsuitable for some patients [27]. Research into new supplements, especially high‐quality protein supplements that are free of side effects, is gaining attention. EWP is low in phosphorus, fat, and carbohydrates, and rich in high‐quality protein, despite its potential benefits for phosphorus control and nutritional status. Given its low cost and palatability, EWP is a feasible supplement candidate for this population. Materials and Methods Study Design and Participants This 8‐week double‐blind, placebo‐controlled RCT was designed and reported in accordance with CONSORT guidelines and conducted at Imam Reza Hospital, Tabriz University of Medical Sciences, Tabriz, Iran. Participants were interviewed, and a questionnaire concerning demographics, the International Physical Activity Questionnaire ‐ Short Form (IPAQ) [28], a 3‐day dietary record (one dialysis day and two non‐dialysis days), medication use, dialysis duration, urine output, and smoking status was completed. Inclusion criteria: age 40 to 70, three HD sessions a week, at least 3 months of HD history, and patients with type 2 diabetes mellitus. Exclusion criteria: having an underlying disease (heart failure, acute liver disease, thyroid disease, and malignancy), taking Egg white supplements before entering the project, smoking, alcohol, and hookah use, taking steroidal and nonsteroidal anti‐inflammatory drugs, severe/allergic reaction to supplements, placebo, and cocoa powder, and conditions such as uncontrolled high blood pressure or severe electrolyte imbalance that could interfere with the study results. Withdrawal criteria: unwillingness to continue participating in the study, travel or transfer to another HD center, death, and less than 90% adherence to supplementation. Patients were randomly assigned to EWP or placebo. Recruitment occurred from May 25 to June 10, 2025. Neither patients nor the public were involved in study design or conduct. Intervention The intervention group received 30 grams of EWP (7 egg whites; 22 grams protein, 105 kcal) with cocoa flavor in 120 mL water, three times weekly during dialysis. The placebo group received cocoa powder in 150 mL of water (similar taste/smell without EWP). Dose was based on Azmandian et al. The taste and aroma of the supplement and placebo were tested by various individuals and reported to be pleasant and usable. The supplements and placebo were prepared by Pamin Industrial Group in completely similar packaging, color, and smell. Follow‐up Investigators directly administered the supplement/placebo during HD sessions, ensuring complete consumption using a straw. Participants maintained their usual diet and physical activity, with investigator contact numbers provided for questions. Follow‐up lasted 8 weeks. Outcomes The primary outcome was the change in low‐density lipoprotein cholesterol (LDL‐c) from baseline to the end of the trial. Secondary outcomes were SOD, MDA, Total Antioxidant Capacity (TAC), change in weight, Body Mass Index (BMI), dietary protein, protein/weight ratio, dietary carbohydrate, dietary fat, dietary intake, and serum levels of sodium, potassium, phosphorus, fasting blood sugar (FBS), Albumin, and lipid profile (other than LDL‐c). Biochemical Assessment After a 12 h fast, 7 mL venous blood was collected at baseline and study end. Participants avoided physical activity for 30 min before sampling. Serum was separated by centrifugation (3000 rpm, 5 min) and stored at −60°C until analysis. TAC (Cat. No. ZB‐TAC‐96 A; intra‐assay CV < 3.4%, inter‐assay CV < 4.2%) and SOD (Cat. No. ZB‐SOD‐96 A; intra‐assay CV < 5.8%, inter‐assay CV < 7.2%) were measured using colorimetric kits (ZellBio GmbH, Germany). MDA was measured using a TBARS assay. Anthropometric Indices A stadiometer, precise to 0.1 cm, was employed to assess the height of participants as they stood adjacent to the wall. The weight was measured using a weighing scale (Seca, Hamburg, Germany), with participants attired in minimal clothing and barefoot, rounded to the nearest 0.1 kg. Safety and Harms Assessment Side effects were characterized as any unfavorable clinical or laboratory changes, including allergic reactions, vomiting, nausea, abdominal discomfort, or variations in blood pressure. The harms were systematically evaluated during each HD session via direct questioning by the investigators and examination of medical records. Furthermore, spontaneous reports from participants were documented throughout the intervention duration. Sample Size Calculation The sample size was calculated based on the primary outcome of LDL‐c. Using a standard deviation (SD) and mean change (d) obtained from a study by Kooshki et al. Kooshki et al. [29], and with a type I error (α) of 0.05% and 80% power (type II error, β = 0.20), the calculation determined that 19 participants were required per group. Randomization An independent statistician who was not involved in patient recruitment or outcome assessment generated a random allocation sequence using RAS software with a block randomization method (block size of 4), stratified by BMI (25–30 vs. 18.5–25 kg/m2), gender (male/female), and duration of dialysis (< 5 years, 5–10 years, > 10 years). A total of 44 eligible patients were randomly assigned in a 1:1 ratio to receive either EWP or placebo. Allocation concealment: The supplement supplier prepared identical bottles containing either EWP or placebo, labeled only with codes “0” and “1”. The code allocation was not disclosed to the research team, participants, outcome assessors, or statisticians until after the final data analysis was completed. The trial coordinator (A.B) screened patients for eligibility, obtained written informed consent, and enrolled participants. After enrollment, the next available sequentially numbered, opaque, sealed container was opened to reveal the bottle code (“0” or “1”), which was then assigned to the participant. Thus, (A.B) assigned participants to their groups but remained blinded to whether “0” or “1” represented EWP or placebo. Blinding This was a double‐blind trial. Participants and outcome assessors (also laboratory personnel performing biochemical assays) were all blinded to group allocation. Only the supplement supplier held the unblinded code. The blinding integrity was maintained throughout the 8‐week intervention period. Statistical Analysis All analyses were performed using IBM SPSS Statistics (Version 27.0, IBM Corp., Armonk, NY, USA). The analysis was conducted on a modified intention‐to‐treat (mITT) population, defined as all randomized participants who received at least one dose of the intervention and had at least one post‐baseline assessment of the study outcomes. Normality of continuous variables was assessed using the Kolmogorov‐Smirnov test. Data are presented as mean ± standard deviation (SD) for continuous variables and as number (percentage) for categorical variables. For between‐group comparisons, an analysis of covariance (ANCOVA) was applied to post‐intervention values, with baseline measurement of the respective outcome, changes in BMI, physical activity, and energy intake included as covariates. For within‐group comparisons, paired t‐tests were used. Independent t‐tests were used for unadjusted between‐group comparisons. Results are reported as mean differences (MD) with 95% confidence intervals (CIs) for all outcomes. A two‐sided significance level of α = 0.05 was pre‐specified. The reporting of statistical analyses follows the recommendations of Assel et al. (2018) for clinical research. Ethical Consideration Volunteers completed a written informed consent form following an explanation of the study protocol; participation in this study was entirely voluntary, and their decision to participate or withdraw would not affect their routine clinical care, their relationship with their treating physicians, or any aspect of their dialysis treatment at Imam Reza Hospital. The ethics committee of Tabriz University of Medical Sciences, Tabriz, Iran, provided ethics approval in alignment with the Declaration of Helsinki (approval ID: IR. TBZMED.REC.1404.072). The trial was prospectively registered in the Iranian Registry of Clinical Trials (IRCT) on May 20, 2025, with the identifier IRCT20110123005670N30 (available at: https://irct.behdasht.gov.ir/trial/82350). Results Participant Characteristics A total of 39 HD patients completed the study. All analyses were performed on the mITT population as prespecified in the Statistical Analysis section. Figure 1 illustrates a flow diagram of the study showing participant enrollment, randomization, follow‐up, and analysis. Table 1 presents the baseline characteristics of participants for both groups. At the beginning of the study, there was no significant difference observed between the EWP and placebo groups concerning Age, Weight, Height, BMI, Duration of dialysis, Hypertension, Education, Income Status, and Physical Activity. CONSORT flow diagram of the study showing participant enrollment, randomization, follow‐up, and analysis. Table 1Baseline characteristics of participants.VariablesEWP group (n = 19)Placebo group (n = 20) p Age (years)62.8 ± 762.3 ± 7.30.85** Weight (kg)77.9 ± 14.883.1 ± 130.25** Height (cm)163.9 ± 8.5165.3 ± 9.50.62** BMI (kg/m2)28.9 ± 530.6 ± 5.80.36** Duration of dialysis (years)3.63 ± 2.193.97 ± 2.620.57** HypertensionYes13 (68.4%)11 (55%)0.39* No6 (31.6%)9 (45%)SexMale11 (57.9%)12 (60%)0.89* Female8 (42.1%)8 (40%)EducationUnder diploma18 (94.7%)16 (80%)0.17* Diploma and higher1 (5.3%)4 (20%)Income statusBelow average10 (52.6%)9 (45%)0.63* Above average9 (47.4%)11 (55%)Physical activityLow13 (68.4%)11 (55%)0.70*** Moderate5 (26.3%)7 (35%)High1 (5.3%)2 (10%) Note: Values are reported as mean ± standard deviation (SD) for quantitative data and frequency (%) for qualitative data. p < 0.05 was considered statistically significant.*Chi‐square.**Independent sample t‐test.***Fisher‐exact test. Baseline characteristics of participants. Note: Values are reported as mean ± standard deviation (SD) for quantitative data and frequency (%) for qualitative data. p < 0.05 was considered statistically significant. Chi‐square. Independent sample t‐test. Fisher‐exact test. Medication and Supplement As shown in Table 2, at baseline, both groups were similar regarding all potential confounding medications and supplements (p > 0.05). Throughout the intervention period, there were no significant changes in medication use within either group. At the end of the study, the distribution of medication use remained consistent between the groups (p > 0.05). Consequently, any observed changes in the study outcomes can be attributed to the EWP rather than differences in medication use. Remarkably, neither group used any medications to influence sodium balance. Table 2Comparison of medication and supplement use between the EWP and control groups before and after the intervention.Medication/SupplementEWP group (n = 19)Placebo group (n = 20) p ** Lipid‐loweringBefore intervention13 (65.0%)11 (57.9%)0.76After intervention12 (60.0%)11 (57.9%)> 0.99 p * > 0.99> 0.99AntioxidantBefore intervention20 (100%)19 (100%)> 0.99After intervention20 (100%)19 (100%)> 0.99 p * > 0.99> 0.99Phosphate bindersBefore intervention20 (100%)19 (100%)> 0.99After intervention20 (100%)19 (100%)> 0.99 p * > 0.99> 0.99Potassium‐loweringBefore intervention8 (40.0%)9 (47.4%)0.76After intervention9 (45.0%)10 (52.6%)0.76 p * > 0.99> 0.99AntidiabeticBefore intervention6 (30.0%)4 (21.1%)0.73After intervention5 (25.0%)4 (21.1%)> 0.99 p * > 0.99> 0.99 Notes: Values are reported as frequency (%) for qualitative data. p < 0.05 was considered statistically significant. Lipid‐lowering drugs: Atorvastatin, Fenofibrate, Niacin, Omega‐3; Antioxidant supplements: Nephrovit, Folic acid, Vitamin D (calcitriol, D3), Vitamin B complex, Vitamin E; Phosphate binders: Calcium carbonate, Renagel (sevelamer), Cinacalcet; Antidiabetic drugs: Insulin, Pioglitazone, Linagliptin, Repaglinide, Metformin; Potassium‐lowering drugs: Furosemide/Lasix.*McNemar's test.**Fisher‐exact test. Comparison of medication and supplement use between the EWP and control groups before and after the intervention. Notes: Values are reported as frequency (%) for qualitative data. p < 0.05 was considered statistically significant. Lipid‐lowering drugs: Atorvastatin, Fenofibrate, Niacin, Omega‐3; Antioxidant supplements: Nephrovit, Folic acid, Vitamin D (calcitriol, D3), Vitamin B complex, Vitamin E; Phosphate binders: Calcium carbonate, Renagel (sevelamer), Cinacalcet; Antidiabetic drugs: Insulin, Pioglitazone, Linagliptin, Repaglinide, Metformin; Potassium‐lowering drugs: Furosemide/Lasix. McNemar's test. Fisher‐exact test. Effect of EWP on Nutritional Status Table 3 presents the changes in dietary variables during the intervention. After 8 weeks, participants in the EWP group showed improvement in dietary protein intake (from 55.7 ± 18.4 g/day to 69.9 ± 20.3 g/day; p < 0.001), while the placebo group remained unchanged (p = 0.69). When adjusted for baseline values, post‐intervention protein intake was significantly higher in the EWP group compared with placebo (p = 0.01). A similar pattern was observed for protein intake per kilogram of body weight (kg BW) (p = 0.005). Energy, carbohydrate, and fat intake, as well as body weight and BMI, did not change significantly in either group (p > 0.05). Table 3Effects of Egg white powder supplementation on nutritional status and biochemical parameters in hemodialysis patients.VariablesEWP group (n = 19)Placebo group (n = 20)MD (95% CI), p Weight (kg)Before intervention77.9 ± 14.883.1 ± 13−5.2 (−14.2, 3.8), 0.25** After intervention77.3 ± 14.283 ± 12.2−0.8 (−1.9, 0.3), 0.14a MD (95% CI), p * −0.6 (−1.5, 0.3), 0.16−0.1 (−0.9, 0.7), 0.81BMI (kg/m2)Before intervention28.9 ± 530.6 ± 5.8−1.6 (−5.2, 1.9), 0.36** After intervention28.7 ± 4.830.5 ± 5.5−0.3 (−0.7, 0.1), 0.19a MD (95% CI), p * −0.2 (−0.5, 0.1), 0.19−0.1 (−0.4, 0.3), 0.83Energy (kcal/day)Before intervention1474.2 ± 430.11507.9 ± 391.2−33.8 (−300.3, 232.7), 0.80** After intervention1563.2 ± 357.81570.5 ± 406.2−15.1 (−193.4, 163.4), 0.86a MD (95% CI), p * 89.1 (−69.0, 247.1), 0.2563 (−68.4, 193.6), 0.33Protein (g/day)Before intervention55.7 ± 18.467.4 ± 20.4−11.7 (−24.3, 0.9), 0.07** After intervention69.9 ± 20.366 ± 18.412.7 (3.6, 21.9), 0.01b MD (95% CI), p * 14.01 (6.8, 21.5), < 0.001−1.4 (−8.7, 5.8), 0.69Protein per weight (g/kg BW)Before intervention0.72 ± 0.220.82 ± 0.24−0.1 (−0.2, 0.1), 0.21** After intervention0.92 ± 0.250.81 ± 0.240.2 (0.1, 0.3), 0.005b MD (95% CI), p * 0.19 (0.10, 0.28), < 0.001−0.01 (−0.10, 0.08), 0.81Carbohydrate (g/day)Before intervention171.5 ± 57.3168.1 ± 42.73.4 (−29.2, 36.1), 0.83** After intervention183.7 ± 59.1189 ± 73.5−11.1 (−39.2, 17.1), 0.69b MD (95% CI), p 12.2 (−14.5, 39.0), 0.3520.9 (−8.8, 50.6), 0.16Fat (g/day)Before intervention66.2 ± 25.566.4 ± 27.2−0.2 (−17.4, 16.9), 0.98** After intervention59.5 ± 14.362.2 ± 22.8−2.9 (−12.3, 6.4), 0.58b MD (95% CI), p −6.6 (−18.1, 4.9), 0.22−4.2 (−11.1, 2.4), 0.24Serum Sodium (mEq/L)Before intervention158.8 ± 5.8155 ± 9.23.8 (−1.2, 8.8), 0.13** After intervention150.6 ± 4.5149.2 ± 6.10.4 (−2.3, 3.1), 0.76a MD (95% CI), p * −8.2 (−10.3, −6.1), < 0.001−5.8 (−8.9, −2.7), 0.001Serum Potassium (mEq/L)Before intervention6 ± 0.475.81 ± 0.560.2 (−0.1, 0.5), 0.27** After intervention5.29 ± 0.275.33 ± 0.29−0.1 (−0.2, 0.1), 0.42a MD (95% CI), p * −0.7 (−0.9, −0.4), < 0.001−0.5 (−0.7, −0.3), < 0.001Serum Phosphorus (mg/dL)Before intervention6.83 ± 1.046.22 ± 1.30.6 (−0.2, 1.4), 0.12After intervention5.25 ± 1.25.9 ± 1.44−1.1 (−1.8, −0.3), 0.01a MD (95% CI), p −1.6 (−2.1, −1.0), < 0.001−0.3 (−0.8, 0.2), 0.20 Note: Values are reported as mean ± standard deviation (SD). p < 0.05 was considered statistically significant.Abbreviations: CI, confidence interval; MD, mean difference. a ANCOVA with adjustment for baseline values. b ANCOVA with adjustment for baseline values, changes in energy intake, changes in BMI, and physical activity.*Paired samples t‐test.**Independent sample t‐test. Effects of Egg white powder supplementation on nutritional status and biochemical parameters in hemodialysis patients. Note: Values are reported as mean ± standard deviation (SD). p < 0.05 was considered statistically significant. Abbreviations: CI, confidence interval; MD, mean difference. ANCOVA with adjustment for baseline values. ANCOVA with adjustment for baseline values, changes in energy intake, changes in BMI, and physical activity. Paired samples t‐test. Independent sample t‐test. Regarding biochemical markers, both groups experienced only slight reductions in serum sodium and potassium within‐group, but the EWP group showed a significant decrease in serum phosphorus (p < 0.001). Also, the post‐intervention phosphorus level was significantly lower in the EWP group (5.25 ± 1.2 mg/dL) compared with the placebo group (5.9 ± 1.44 mg/dL) after adjusting for baseline values and changes in phosphorus dietary intake (p = 0.01). (Table 3). Effect of EWP on Biochemical Indices After 8 weeks, FBS showed a significant between‐group mean difference (p = 0.03). However, this was driven primarily by a borderline increase in the placebo group (from 126.6 ± 39.5 to 151.8 ± 63.1 mg/dL; p = 0.06) rather than a significant decrease in the EWP group (from 130 ± 47.4 to 122.8 ± 39.2 mg/dL; p = 0.26) (Table 4). Table 4Effects of Egg white powder supplementation on blood glucose, lipid profile, and serum albumin in hemodialysis patients.VariablesEWP group (n = 19)Placebo group (n = 20)MD (95% CI), p Fasting blood sugar (mg/dL)Before intervention130 ± 47.4126.6 ± 39.53.4 (−24.8, 31.7), 0.81** After intervention122.8 ± 39.2151.8 ± 63.1−30.7 (3.1, 58.3), 0.03 a MD (95% CI), p * −7.2 (−20.2, 5.9), 0.2625.2 (−0.1, 50.6), 0.06Triglyceride (mg/dL)Before intervention226.4 ± 117.9224.4 ± 93.42.1 (−66.8, 70.9), 0.95** After intervention216.8 ± 86.9265 ± 94.2−57.1 (−96.8, −17.4), 0.01a MD (95% CI), p * −9.6 (−50.5, 31.3), 0.6340.6 (14.7, 66.5), 0.004Total Cholesterol (mg/dL)Before intervention160.4 ± 36.1135 ± 3425.4 (2.5, 48.3), 0.03** After intervention151.9 ± 27.1185.3 ± 63.8−61.2 (−86.0, −36.4), < 0.001 a MD (95% CI), p * −8.5 (−22.1, 5.2), 0.2150.4 (32.3, 68.3), < 0.001LDL Cholesterol (mg/dL)Before intervention75.3 ± 27.950.3 ± 29.324.9 (6.3, 43.5), 0.01** After intervention66.9 ± 25.794.4 ± 64.1−60.1 (−84.9, −35.3), < 0.001 a MD (95% CI), p * −8.3 (−19.1, 2.4), 0.12144.1 (24.6, 63.5), < 0.001HDL Cholesterol (mg/dL)Before intervention41.2 ± 5.240.5 ± 4.20.7 (−2.4, 3.7), 0.66** After intervention41.6 ± 5.838.7 ± 6.62.3 (−1.5, 6.3), 0.21 a MD (95% CI), p * 0.4 (−2.2, 3.1), 0.74−1.8 (−4.7, 1.0), 0.19Albumin (mg/dL)Before intervention3.65 ± 0.623.76 ± 0.66−0.1 (−0.5, 0.3), 0.58** After intervention4.15 ± 0.693.57 ± 0.560.7 (0.1, 1.0), < 0.001b MD (95% CI), p * 0.5 (0.3, 0.7), < 0.001−0.2 (−0.4, 0.001), 0.06 Note: Values are reported as mean ± standard deviation (SD). p < 0.05 was considered statistically significant.Abbreviations: CI, confidence interval; MD, mean difference. a ANCOVA with adjustment for baseline values, changes in energy and fat intake, changes in BMI, and physical activity. b ANCOVA with adjustment for baseline values, changes in energy, and protein intake.*Paired samples t‐test.**Independent sample t‐test. Effects of Egg white powder supplementation on blood glucose, lipid profile, and serum albumin in hemodialysis patients. Note: Values are reported as mean ± standard deviation (SD). p < 0.05 was considered statistically significant. Abbreviations: CI, confidence interval; MD, mean difference. ANCOVA with adjustment for baseline values, changes in energy and fat intake, changes in BMI, and physical activity. ANCOVA with adjustment for baseline values, changes in energy, and protein intake. Paired samples t‐test. Independent sample t‐test. Triglycerides (TG) decreased slightly in the EWP group (p = 0.63) but rose in the placebo group (p = 0.004), resulting in a significant difference between groups (p = 0.01). There was a significant difference between EWP and placebo in Total cholesterol (TC) (EWP: 151.9 ± 27.1 mg/dL; placebo: 185.3 ± 63.8 mg/dL; p < 0.001), and LDL‐c (EWP: 66.9 ± 25.7 mg/dL; placebo: 94.4 ± 64.1 mg/dL; p < 0.001) after adjustment. In contrast, HDL‐c had a non‐significant improvement in the EWP group after intervention (from 41.2 ± 5.2 to 41.6 ± 5.8 mg/dL; p = 0.74) (Table 4). Importantly, serum albumin increased markedly in the EWP group (from 3.65 ± 0.62 to 4.15 ± 0.69 g/dL; p < 0.001) compared with a slight, non‐significant reduction in the placebo group (p = 0.06). The between‐group difference after intervention was highly significant after adjustment for baseline values, changes in energy, and protein intake (p < 0.001) (Table 4). Effect of EWP on Oxidative Stress Markers Following supplementation, the EWP group showed significant improvements in antioxidant status: TAC increased (from 7.93 ± 1.76 to 9.63 ± 2.8 µmol/L; p = 0.01), and SOD rose substantially (from 15.19 ± 5.27 to 18.83 ± 5.13 U/mL; p = 0.003), while MDA levels decreased noticeably (from 2.62 ± 0.76 to 1.94 ± 0.49 nmol/mL; p < 0.001). In contrast, the placebo group showed no significant changes in any OS markers (p > 0.05). Post‐intervention comparisons revealed higher TAC (p = 0.02), higher SOD (p = 0.003), and lower MDA (p < 0.001) in the EWP group compared to placebo with adjustment for baseline values, changes in energy intake, changes in BMI, and physical activity (Table 5). Table 5Effect of Egg white powder supplementation on oxidative stress markers in hemodialysis patients.VariablesEWP group (n = 19)Placebo group (n = 20)MD (95% CI), p TAC (µmol/L)Before intervention7.93 ± 1.769.11 ± 3.55−1.2 (−1.0, 0.7), 0.20** After intervention9.63 ± 2.88.22 ± 2.852.0 (0.2, 3.8), 0.02a MD (95% CI), p * 1.7 (0.4, 2.9), 0.01−0.9 (−2.6, 0.8), 0.28MDA (nmol/mL)Before intervention2.62 ± 0.762.5 ± 0.880.1 (−0.4, 0.6), 0.66** After intervention1.94 ± 0.492.81 ± 0.99−1.0 (−1.5, −0.4), < 0.001a MD (95% CI), p * −0.7 (−1.0, −0.4), < 0.0010.3 (−0.2, 0.8), 0.22SOD (U/mL)Before intervention15.19 ± 5.2716.25 ± 5.89−1.1 (−4.7, 2.6), 0.56** After intervention18.83 ± 5.1313.46 ± 5.845.7 (2.1, 9.3), 0.003a MD (95% CI), p * −0.6 (1.1, 1.4), 0.003−2.8 (−6.6, 1.0), 0.14SOD/MDA ratioBefore intervention6.04 ± 2.337.06 ± 3.29−1.0 (−2.9, 0.80, 0.27** After intervention10.31 ± 4.175.01 ± 2.045.8 (3.6, 8.1), < 0.001a MD (95% CI), p * 4.3 (2.4, 6.1), < 0.001−2.1 (−3.9, −0.2), 0.03 Notes: Values are reported as mean ± standard deviation (SD). p < 0.05 was considered statistically significant.Abbreviations: CI, confidence interval; MD, mean difference. a ANCOVA with adjustment for baseline values, changes in energy intake, changes in BMI, and physical activity.*Paired samples t‐test.**Independent sample t‐test. Effect of Egg white powder supplementation on oxidative stress markers in hemodialysis patients. Notes: Values are reported as mean ± standard deviation (SD). p < 0.05 was considered statistically significant. Abbreviations: CI, confidence interval; MD, mean difference. ANCOVA with adjustment for baseline values, changes in energy intake, changes in BMI, and physical activity. Paired samples t‐test. Independent sample t‐test. Safety and Harms A total of three serious adverse events occurred: two deaths due to Myocardial Infarction, and one hospitalization due to infection in the EWP group. All serious adverse events were independently reviewed by the attending nephrologist (J.S.) and determined to be unrelated to the study intervention. The deaths were attributed to underlying comorbidities common in diabetic HD patients (cardiovascular disease). The hospitalization for infection was also judged to be unrelated to EWP or placebo consumption. No other adverse events were reported in either group (Table S1). Discussion This study considered the effect of EWP supplementation on nutritional status, biochemical, and OS parameters in HD patients. Over 8 weeks of intervention, EWP resulted in significant improvements in protein intake, serum albumin levels, FBS, lipid profile, phosphorus levels, and antioxidant capacity in comparison to the placebo. PEW represents a major concern for HD patients [30], and increasing high‐quality protein intake is a crucial nutritional objective for them [30]. Although serum albumin increased, its interpretation is cautious because albumin is influenced by inflammation, hydration, and residual renal function, not solely by protein intake. Despite a significant rise in protein intake, the mean intake (0.92 g/kg/day) remained below the recommended 1–1.2 g/kg/day, indicating that additional dietary support may be needed. EWP also reduced serum phosphorus, reflecting the favorable phosphorus‐to‐protein ratio of egg white [31]. Whether this effect is sustained long‐term or reduces the need for phosphate binders is unknown. The results of our study were in line with Javadian et al. [32] findings, who reported that 24 g/day of egg white protein improved nutritional status and serum albumin in HD patients without raising phosphorus levels. Unlike our trial, the study by Javadian et al. [32] did not focus on diabetic patients or report baseline dietary intake [32]. Similarly, Azmandian et al. [33] found that replacing meat with egg white protein for 3 months reduced serum phosphorus while maintaining adequate albumin concentrations [33]. The Azmandian et al. study is limited by its open‐label design and per‐protocol analysis. Furthermore, Guida et al. [34] designed a clinical trial that enrolled 23 HD patients with hyperphosphatemia. After supplementation with 22 g of egg white protein, 3 times/week, replacing meat, blood phosphorus levels were significantly lower in the intervention group than in the control group compared to the baseline, but acknowledged limitations: short duration (3 months), potential regression‐to‐the‐mean bias, and insufficient power for secondary outcomes. Guida et al., [34]. Participants receiving EWP exhibited reduced levels of TG, TC, and LDL‐c in comparison to the placebo group. These lipid‐lowering effects are consistent with earlier reports on egg white proteins and peptides. Matsuoka et al. [35] demonstrated in an RCT that the intake of lactic fermented egg whites significantly decreased TC and LDL‐c levels in mildly hypercholesterolemic adults [35]. Earlier work by Nagaoka et al. indicated that ovomucin, a glycoprotein component of egg white, can mitigate hypercholesterolemia in rats by decreasing the micellar solubility and intestinal absorption of cholesterol [36]. Furthermore, egg white peptides exhibit potent antioxidant and ACE‐inhibitory properties, and may modulate hepatic cholesterol metabolism through bioactive dipeptides [37, 38]. The between‐group difference in FBS was largely due to an increase in the placebo group. These findings are preliminary and do not confirm a glycemic benefit for EWP. Although human data specifically on egg white and FBS are limited, several clinical studies have indicated that the consumption of egg white or egg protein alongside or prior to a carbohydrate intake can mitigate postprandial glycemia. A 2018 investigation by McDonald et al. observed decreases in postprandial glucose levels among prediabetic men in an intervention group that consumed 7 egg whites with 75 g of glucose, in contrast to a placebo group [39]. Additionally, short‐term protein preload trials conducted by Gibson et al. in 2019 reported a reduction in postprandial glycemia following an egg protein preload in 24 healthy adults [40]. Preclinical research indicates that egg white hydrolysates may enhance insulin signaling and glucose uptake via IRS‐1/Akt/GLUT4 pathways, as well as stimulate the release of incretin hormones from intestinal cells [41, 42, 43]. In the present study, TAC and SOD activity increased while MDA levels decreased after 8 weeks of EWP supplementation, indicating an improved capacity to mitigate lipid peroxidation and ROS. Similar antioxidant effects of egg white hydrolysates and egg‐derived peptides have been reported in both animal and human research. A study conducted in 2016 by Raymond et al. on obese rats, which were administered pepsin‐hydrolyzed egg white, demonstrated a significant reduction in plasma MDA levels and OS [44]. Chen et al. [45] indicated that egg white hydrolysates reduced lipid peroxidation and increased SOD in liver injury models induced by carbon tetrachloride [45]. In a RCT, Oe et al. [46] found that a single administration of egg white hydrolysate elevated plasma antioxidant potential, and a regimen of daily intake (5 g/day) over 2 weeks led to a reduction in subjective mental fatigue among athletes, which was attributed to enhanced systemic antioxidant capacity [46]. Additionally, a study by Junior et al. in 2024 revealed that oral intake of egg white hydrolysates for 4 weeks resulted in a notable decrease in MDA concentration, while SOD levels in brain tissue increased [47]. The following mechanistic interpretations are speculative and hypothesis‐generating, based primarily on in vitro or animal studies, and remain to be confirmed in dedicated human studies. Proposed mechanisms include direct radical scavenging, Nrf2‐mediated up‐regulation of antioxidant enzymes, metal chelation, and anti‐inflammatory effects. However, these are speculative and derived from preclinical studies [47, 48, 49, 50]. Strengths and Limitations This study represents one of the initial RCTs aimed at assessing the impact of EWP supplementation on both nutritional and OS in HD patients, facilitating a more comprehensive understanding of the physiological effects of EWP. A significant strength of this research lies in its double‐blind, placebo‐controlled design. Furthermore, the incorporation of a phosphorus‐free protein source guarantees that protein consumption can be increased safely without negatively impacting phosphate levels—a critical issue for this demographic. Nevertheless, it is essential to recognize several limitations. First, the sample size was small (39 completers), which limits the precision of effect estimates and the generalizability of the findings. Second, EWP was associated with lower serum phosphorus at 8 weeks, but whether this effect is sustained long‐term or reduces the need for phosphate binders is unknown. Third, the short intervention duration is a major limitation. While adequate for pilot metabolic changes, it does not allow assessment of long‐term outcomes such as hospitalization, mortality, or sustained PEW reversal. Fourth, this was a single‐center study, which may limit external validity. Additionally, dietary intake was determined through self‐reported 24‐h recalls, which could present recall bias. Conclusion In this single‐center, 8‐week RCT, EWP supplementation significantly improved protein intake, serum albumin, lipid profile (LDL‐c, TC, TG), and oxidative stress markers (TAC, SOD, MDA) in diabetic HD patients, without increasing serum phosphorus. No intervention‐related adverse effects were observed. No significant effects were observed for BMI, energy intake, or HDL‐c. However, these findings are preliminary. The small sample size, short intervention duration, and single‐center design are limitations that preclude definitive conclusions. The mechanistic interpretations provided in the Discussion are speculative and require confirmation in dedicated human studies. Future research would extend intervention durations (≥ 3–6 months) to evaluate the long‐term nutritional, metabolic, and renal effects of EWP in HD patients. It is advisable to conduct larger multicenter studies to enhance the generalizability of the results and validate the existing findings. Eventually, the evaluation of clinical outcomes, including renal parameters, inflammatory markers, sleep quality, and quality of life, would strengthen the evidence supporting the integration of EWP into renal nutrition guidelines. Until such evidence becomes available, our results should be considered hypothesis‐generating rather than practice‐changing. Author Contributions Arvin Babaei: conceptualization, investigation, writing – original draft, methodology, visualization, data curation, software, validation. Hamta Abdollah Niya: investigation, writing – original draft, methodology. Soudabeh Hamedi‐Shahraki: formal analysis, validation. Javid Safa: conceptualization, supervision, investigation. Ali Tarighat‐Esfanjani: conceptualization, investigation, funding acquisition, resources, supervision, project administration, writing – review and editing. Conflicts of Interest The author declared that there is no conflict of interest. Pamin Industrial Group provided the EWP supplement and placebo but had no role in the study design, data collection, data analysis, interpretation of results, manuscript preparation, or the decision to submit the manuscript for publication. The funder (Vice‐Chancellor for Research and Technology of Tabriz University of Medical Sciences) also had no role in any aspect of the study. Ethics Statement The study protocol was approved by the Ethics Committee of Tabriz University of Medical Sciences (Approval Code: IR. TBZMED. REC.1404.072). Consent The authors have nothing to report. Supporting information Table S1: Summary of adverse events. Acknowledgments The authors sincerely express gratitude to all the participants and the dedicated staff of the research center for their valuable contributions to this trial. We also extend our deep appreciation to Pamin Industrial Group (Tabriz, Iran) for kindly providing the EWP supplement and placebo used in this clinical study. Special thanks are due to the hemodialysis centers of Imam Reza Hospital in Tabriz for their invaluable support throughout the research process. This study was conducted as part of the MSc dissertation of Arvin Babaei, submitted to Tabriz University of Medical Sciences. This study was funded by the Vice‐Chancellor for Research and Technology of Tabriz University of Medical Sciences (Tabriz, Iran) [Grant Number 75766]. Data Availability Statement The data that support the findings of this study are available from the corresponding author upon reasonable request. References Associated Data Supplementary Materials Table S1: Summary of adverse events. Data Availability Statement The data that support the findings of this study are available from the corresponding author upon reasonable request.